Change Initiative https://validator.w3.org/feed/docs/rss2.html US Policy Horizon Series: From Washington to the World Most-Favoured Nation Pricing: What Do the Experts Think?  Germany’s drug-pricing dilemma: Why Europe’s pivotal market holds the key to the MFN debate MEDIA: ISPOR 2026 – Inside the third plenary: Can global markets adapt to the ripple effects of US pricing policy? MEDIA: Trump’s drug pricing war comes for Germany Why President Trump’s generic drug tariffs are unlikely to fix America’s supply problem Is the revised Congressional Budget Office model of new drug development fit for purpose? Privacy and terms From Washington to the World: Resource Library Most Favored Nation pricing: what it means for policy, patients and pharma Trump Administration announces 100% tariffs on pharmaceuticals Cookies Supreme Court rejects Trump’s tariffs: What does this mean for pharma? Three Models of MFN Announced Contact Us Home Financing Prevention: Unlocking Investment in a Healthier Future Our Research Areas Partner With Us Europe’s pharmaceutical policy choices – And what the United States stands to learn How US drug pricing reforms are reshaping biopharma investment and innovation